{
    "root": "39a1a690-70fe-955f-7de2-60acd086d1d5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Teriparatide",
    "value": "20250509",
    "ingredients": [
        {
            "name": "TERIPARATIDE",
            "code": "10T9CSU89I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135983"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "SODIUM ACETATE ANHYDROUS",
            "code": "NVG71ZZ7P0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "WATER O-18",
            "code": "7QV8F8BYNJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "teriparatide injection indicated . treatment postmenopausal women osteoporosis high risk fracture ( defined herein history osteoporotic fracture multiple risk factors fracture ) failed intolerant available osteoporosis therapy . postmenopausal women osteoporosis , teriparatide injection reduces risk vertebral nonvertebral fractures . increase bone mass men primary hypogonadal osteoporosis high risk fracture failed intolerant available osteoporosis therapy . treatment men women osteoporosis associated sustained systemic glucocorticoid therapy ( daily equivalent 5 mg greater prednisone ) high risk fracture failed intolerant available osteoporosis therapy .",
        "doid_entities": [
            {
                "text": "osteoporosis (DOID:11476)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11476"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended 20 mcg subcutaneously day ( 2.1 ) consider supplemental calcium vitamin based individual patient needs ( 2.1 ) administer subcutaneous injection thigh abdominal region ( 2.2 ) administer initially circumstances patient sit lie symptoms orthostatic hypotension occur ( 2.2 ) teriparatide 2 years patient \u2019 lifetime considered patient remains returned high risk fracture ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "teriparatide injection clear colorless solution , available single-patient-use prefilled delivery device ( pen ) following package size : 600 mcg/2.4 ml ( 250 mcg/ml ) [ containing 28 daily doses 20 mcg ] ndc 60505-6188-0 .",
    "adverseReactions": "teriparatide injection contraindicated patients hypersensitivity teriparatide excipients . hypersensitivity included angioedema anaphylaxis [ ( 6.3 ) ] .",
    "indications_original": "Teriparatide injection is indicated.\n                  \n                     For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures.\n                     To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have\u00a0failed or are\u00a0intolerant to other available\u00a0osteoporosis therapy. \n                     For\u00a0the treatment of men and women\u00a0with osteoporosis\u00a0associated\u00a0with sustained systemic\u00a0glucocorticoid\u00a0therapy (daily dosage equivalent to\u00a05 mg or\u00a0greater of prednisone)\u00a0at high risk for fracture or\u00a0who\u00a0have failed or are intolerant\u00a0to other\u00a0available osteoporosis\u00a0therapy.",
    "contraindications_original": "Recommended\u00a0dosage\u00a0is\u00a020\u00a0mcg\u00a0subcutaneously\u00a0once\u00a0a\u00a0day\u00a0( 2.1 ) Consider supplemental calcium and Vitamin D based on\u00a0individual patient needs (2.1) Administer as\u00a0a\u00a0subcutaneous\u00a0injection\u00a0into\u00a0the\u00a0thigh\u00a0or\u00a0abdominal\u00a0region\u00a0(2.2) Administer initially\u00a0under\u00a0circumstances\u00a0in\u00a0which\u00a0the\u00a0patient can\u00a0sit\u00a0or\u00a0lie\u00a0down\u00a0if\u00a0symptoms of\u00a0orthostatic\u00a0hypotension\u00a0occur\u00a0(2.2) Use\u00a0of\u00a0\u00a0teriparatide for\u00a0more\u00a0than\u00a02\u00a0years\u00a0during\u00a0a\u00a0patient\u2019s\u00a0lifetime\u00a0should only be considered if a patient remains at or has returned to having a high risk for fracture\u00a0\u00a0(2.3)",
    "warningsAndPrecautions_original": "Teriparatide Injection is a clear and colorless solution, available as single-patient-use prefilled delivery device (pen) in the following package size:\n                        \n                           600 mcg/2.4 mL (250 mcg/mL) [containing 28 daily doses of 20 mcg] NDC 60505-6188-0.",
    "adverseReactions_original": "Teriparatide injection is contraindicated in patients with hypersensitivity to\u00a0teriparatide\u00a0or to any of its excipients. Hypersensitivity\u00a0reactions have included angioedema and\u00a0anaphylaxis [see Adverse Reactions (6.3)].",
    "drug": [
        {
            "name": "Teriparatide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135983"
        }
    ]
}